Lupin begins FY27 with a significant rise in sales, outpacing previous growth and strengthening its foothold across the US, India, and emerging markets, supported by its focus on complex generics and specialised products.
Lupin has opened FY27 with a sharp rise in sales, as the drugmaker continued to benefit from strength in the US, India, other developed markets and emerging markets. Business Today TV reported that revenue climbed 33.3% year on year to ₹8,217 crore in the quarter, while EBITDA rose 42.8% to ₹2,580 crore and profit after tax increased 16% to ₹1,417 crore. The company said the latest figures reflected both broad-based growth and further improvement in profitability.
The update builds on a stronger run for Lupin over the past year. In its FY26 results, the Mumbai-based company reported revenue of ₹27,488 crore, up nearly 24% from the previous year, with EBITDA rising 55% to ₹8,160 crore and profit after tax up 62% to ₹5,355 crore, according to company disclosures and market reports. A particularly strong US performance helped drive that momentum, with the business accounting for 40% of total sales in one company update and expanding 47% year on year to ₹2,762 crore.
Ramesh Swaminathan, Lupin’s executive director, global chief financial officer and head of IT and API Plus SBU, discussed the results with Business Today TV, focusing on the company’s product pipeline, research spending, US business and outlook for the rest of FY27. In an earlier company statement, Lupin said it was leaning on complex generics, respiratory products and targeted speciality acquisitions to sustain growth, with the United States remaining its biggest market and a key driver of earnings.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
